Glaxo India Share Price
GlaxoSmithKline Pharmaceuticals Ltd., commonly known as GSK India, is a leading pharmaceutical company operating in India. As a subsidiary of GlaxoSmithKline plc, GSK India has established itself as a significant player in the Indian healthcare sector. The company’s stock is listed on the National Stock Exchange (NSE) under the ticker symbol GLAXO. Investors and analysts closely monitor GSK India’s share price to assess the company’s financial health, market performance, and future prospects.
Current Share Price and Market Performance
As of August 29, 2025, GSK India’s share price on the NSE stood at ₹2,768.50. This reflects a 1.40% increase from the previous trading session, indicating positive investor sentiment. The company’s stock has experienced fluctuations over the past year, with a 52-week high of ₹3,515.95 and a low of ₹1,924.30. These variations highlight the dynamic nature of the pharmaceutical sector and the impact of market conditions on stock performance.
Market Capitalization and Valuation Metrics
GSK India’s market capitalization is approximately ₹47,254.12 crore, positioning it as a mid-cap company within the Indian pharmaceutical industry. The company’s price-to-earnings (P/E) ratio is 49.73, suggesting a premium valuation compared to some industry peers. Additionally, the price-to-book (P/B) ratio stands at 24.22, reflecting investor expectations for future growth and profitability.
Dividend Policy
GSK India has a history of rewarding its shareholders through dividends. The company declared a final dividend of ₹42.00 per share on May 30, 2025, translating to a dividend yield of approximately 1.94%. This consistent dividend payout underscores the company’s commitment to delivering value to its investors.
Financial Performance Overview
In the fiscal year 2024, GSK India reported total income of ₹3,749 crore, marking an 8.56% increase from the previous year. The company’s earnings before interest and tax (EBIT) amounted to ₹928 crore, reflecting a robust operating performance. Net profit for the year was ₹927 crore, a significant rise of 57.23% compared to the prior year. These financial results demonstrate GSK India’s resilience and ability to navigate market challenges effectively.
Quarterly Performance
For the quarter ending June 30, 2025, GSK India reported total income of ₹848.89 crore, a 16.37% decline from the previous quarter. Despite this decrease, the company maintained a healthy EBIT margin of 32.91% and a net profit margin of 24.15%. Earnings per share (EPS) for the quarter stood at ₹12.10, reflecting the company’s continued profitability.
Shareholding Pattern
As of June 30, 2025, the shareholding pattern of GSK India is as follows
- Promoters 75.00%
- Foreign Institutional Investors (FII) 4.89%
- Domestic Institutional Investors (DII) 7.69%
- Mutual Funds 5.17%
- Others 12.42%
This distribution indicates a strong promoter holding, which can contribute to stability in the company’s strategic direction and governance.
Analyst Recommendations and Future Outlook
Analysts have varying perspectives on GSK India’s stock. The median target price for the company’s shares is ₹3,094.75, with estimates ranging from a low of ₹2,600 to a high of ₹3,500. These projections suggest potential upside from the current share price, contingent on factors such as market conditions, regulatory developments, and the company’s performance in its key therapeutic areas.
Industry Position and Competitive Landscape
GSK India operates in a competitive pharmaceutical market, facing competition from both domestic and international players. Key competitors include Abbott India, Cipla, Sun Pharmaceutical Industries, and Dr. Reddy’s Laboratories. Despite this competition, GSK India’s strong brand presence, diverse product portfolio, and commitment to research and development position it favorably in the industry.
GSK India’s share price reflects the company’s strong market position, consistent financial performance, and strategic initiatives aimed at growth. While short-term fluctuations are inherent in the stock market, the company’s fundamentals suggest a promising outlook for long-term investors. Monitoring quarterly results, industry trends, and regulatory changes will be crucial for assessing the future trajectory of GSK India’s stock.
contentReference[oaicite0]